RS2 Healthcare Partners Emerges from Riverside Partners' Rebranding to Focus on Healthcare Investments

RS2 Healthcare Partners Emerges from Riverside Partners' Rebranding

In a significant strategic realignment, Riverside Partners has officially rebranded itself as RS2 Healthcare Partners, underscoring its commitment to healthcare-focused investments. This change marks a pivotal moment for the firm, which has dedicated over three decades to cultivating its expertise in the healthcare sector, particularly within the lower middle market.

The new identity, RS2 Healthcare Partners, reflects the firm's exclusive focus on healthcare investments, which includes pharmaceutical services, medical device contract manufacturing, and technology-driven healthcare solutions. This step formalizes their long-held commitment to becoming a key player in the thriving healthcare landscape.

Alongside this rebranding, the firm has announced the appointment of Craig Stern as Co-Managing Partner, joining David Belluck in leading the organization. Mr. Stern has collaborated with Mr. Belluck for the past 14 years, concentrating solely on healthcare investments. This elevation in leadership signifies the deep-rooted partnership and shared vision between the two leaders as they aim to build a world-class healthcare investment platform.

David Belluck emphasized the strategic shift, stating, "RS2 Healthcare Partners symbolizes our longstanding dedication to lower middle market healthcare investing, bolstered by solid industry relationships and a skilled investment team. We aspire to partner with founders and management teams keen on establishing industry-leading businesses."

The firm’s investment strategy is further supported by an extensive advisory network, inclusive of over 30 executives, clinicians, and technology experts from top healthcare organizations. This collaborative approach is integral to RS2’s strategy, allowing for tailored solutions that meet the evolving needs of the healthcare sector.

In conjunction with the rebrand, RS2 Healthcare Partners has successfully closed a single-asset continuation vehicle for Loftware, Inc., a leading global provider of software solutions for enterprise labeling and artwork management. This transaction illustrates the firm's healthcare proficiency as it underscores Loftware's impressive growth trajectory within the life sciences sector.

The Continuation Vehicle, led by Accel-KKR's Strategic Capital, provides Loftware with vital funding to spearhead future expansion. It also enhances RS2 Healthcare Partners' capacity to pursue new platform investments, complementing its substantial investment history with the firm. Since acquiring Loftware in 2014, RS2 has played a pivotal role in transforming it from a U.S.-centric provider to a globally recognized platform that delivers crucial software applications and solutions for complex supply chains.

During their investment tenure, Loftware has established itself as an indispensable resource for over 10,000 clients across more than 100 countries, generating revenues of approximately $125 million. The growth of Loftware and the firm's tireless efforts in supporting its evolution are testament to RS2's strategic value proposition and commitment to leveraging its healthcare expertise for maximum impact.

As RS2 Healthcare Partners embarks on this new chapter, the leadership asserts a firm conviction regarding the opportunities ahead in healthcare investing. Mr. Stern articulated their vision succinctly: "Our path is defined by an unwavering commitment to excellence, a collaborative culture, and partnerships that foster growth and innovation. We are eager to see where this journey takes us and remain focused on emerging opportunities in the healthcare landscape."

In conclusion, RS2 Healthcare Partners is primed for a future fueled by strategic investment in healthcare, supported by a wealth of experience and a mission to pioneer advancements in the sector. As the firm continues to evolve, its dedication to enhancing the healthcare environment through investment is set to redefine its trajectory, benefitting both partners and communities alike.